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The past few years have brought exciting progress 
in the development of novel forms of immunotherapy of 
cancer. While antibody blockade of negative pathways 
that inhibit T cell function, such as CTLA-4 and PD1, 
has resulted in clinical benefits for patients who have 
failed conventional therapy options, this strategy lacks 
cancer specificity as it also activates T cells with self-
reactive potential. Hence, autoimmunity is a serious side 
effect of anti-CTLA4 and anti-PD1 pathway therapy [1]. 
Engineering T cell specificity provides a strategy to direct 
immunity towards defined cancer-specific or cancer-
associated antigens, thus improving tumor immunity and 
decreasing the risk of autoimmunity. 
Engineering specificity is most commonly achieved 
with retroviral and lentiviral gene transfer vectors that 
equip patient T cells with therapeutic T cell receptors 
(TCRs) or with chimeric antigen receptors (CARs). 
CARs contain the antigen-binding domains of antibody 
molecules fused to transmembrane and cytosolic domains 
required for surface expression and for triggering T cell 
function. The major advantage of CARs is the direct 
recognition of cancer-antigens irrespective of the HLA 
genotype of patients. Hence, the most successful CARs 
that target CD19, a marker of lymphocytes of the B-cell 
linage, provides a treatment option for all patients with 
CD19-positive B-cell malignancies. In contrast, TCRs 
recognize peptide fragments that are presented by highly 
polymorphic HLA molecules. Successful TCR based 
therapy therefore requires not only the expression of the 
relevant antigen in cancer cells but also the selection of 
patients with appropriate HLA alleles. However, a distinct 
advantage of TCRs is that they mediate T cell activation 
when triggered by low concentration of antigen, while T 
cell stimulation by CARs requires relatively high antigen 
expression in cancer cells. 
Jahn and colleagues have tested whether TCRs 
can indeed mediate T cell activation by low antigen 
concentration that would be expected to be insufficient 
for CAR-mediated T cell activation [6]. They have raised 
TCRs against CD20, a B-linage marker that has been 
successfully targeted by therapeutic antibodies. In order 
to circumvent tolerance to CD20, the investigators took 
advantage of the allo-restricted strategy to isolate CD20-
specific T cells from the non-tolerant TCR repertoire of 
allogeneic healthy donors [2]. Using this strategy they have 
raised CD20-specific T cells restricted by HLA-A*02:01 
and B*07:02, two HLA alleles that are frequent in the 
Caucasian population. They went on to demonstrate that 
the CD20-specific T cells were able to recognize and 
efficiently kill B-linage cancer cells expressing low levels 
of the target antigen. In contrast, CD20-specific antibodies 
were unable to mediate complement killing of B-cell 
malignancies expressing low levels of antigen; successful 
antibody attack was only seen against cancer cells with 
high CD20 expression. Following cloning of the genes 
encoding the TCR alpha and beta chains of the CD20-
specific T cells, the authors showed that retroviral TCR 
gene transfer readily converted peripheral lymphocytes 
into therapeutic T cells that effectively killed B-linage 
cancer cells irrespective of the CD20 expression levels.
This study suggests that T cell engineering with 
TCRs and CARs can be complementary. Although 
Jahn and colleagues have not directly compared TCRs 
and CARs with specificity for the same target antigen, 
previously published work has shown that as few at 
one antigenic peptide epitope can be sufficient for TCR 
mediated T cell activation [3, 4]. In contrast, more than 
1000 copies of antigen are usually required when CARs 
mediate T cell activation [5]. Therefore, the down-
modulation of antigen expression levels in patients 
treated with CAR therapy may enable the malignant cells 
to escape attack by CAR-expressing T cells. However, 
such antigen low escape variants would be expected to 
remain susceptible to TCR attack, suggesting that TCR 
gene therapy may be an effective treatment option for 
patients with tumors that have escaped destruction by 
CAR engineered T cells. When combined with allogeneic 
stem cell transplantation, which is often used to treat 
hematological malignancies, TCR gene therapy can offer 
a strategy to selectively attack malignant cells but not 
normal B cells. This can be achieved by selecting stem 
cells, reconstituting the normal B-cell compartment, from 
donors who do not express the HLA allele required for 
TCR recognition. Consequently, the HLA-restricted TCR 
recognition directs T cell attack against patient malignant 
B cells and spares donor-derived B cells, providing a level 
of specificity that cannot be achieved with CARs.
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